AzTrials
AzTrials

Persistent Atrial FibrillationNCT01863472

Catheter Ablation of Drug-refractory Persistent Atrial Fibrillation With the HeartLight(TM) Laser Balloon in Comparison With Irrigated Radiofrequency Current Ablation

A study testing HeartLight(TM) Laser Balloon and irrigated radiofrequency current ablation in people with Persistent Atrial Fibrillation, run by Boris Schmidt at 6 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim of the study is to compare the safety and efficacy of pulmonary vein isolation using the endoscopic ablation system in comparison to irrigated radiofrequency current ablation in patients with drug-refractory persistent atrial fibrillation. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Persistent Atrial Fibrillation
What is being tested?
HeartLight(TM) Laser Balloon and irrigated radiofrequency current ablation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
152 participants
Where
6 sitesin 3 countries
Study dates
Jun 2013to Nov 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 to 80 years
  • persistent atrial fibrillation
  • failure of at least one antiarrhythmic drug
  • others

Who cannot join

  • contraindications for pulmonary vein isolation (PVI)
  • previous PVI attempts
  • inability to be treated with oral anticoagulation
  • presence of intracardiac thrombi
  • pregnancy
  • others

Trial locations and contacts

6 sites in 3 countries.

6 sites in 3 countries

Germany4 sites
  • Herz- und Gefäß-Klinik GmbH Bad Neustadt

    Bad Neustadt an der Saale, Bavaria, 97616

  • Rheinische Friedrich-Wilhelms-Universität Bonn

    Bonn, North Rhine-Westphalia, 53105

  • Cardioangiologisches Centrum Bethanien

    Frankfurt am Main, 60431

  • Städtisches Klinikum Karlsruhe, Medizinische Klinik IV

    Karlsruhe, 76133

Other trials in Germany

Czechia1 site
  • Na Homolce Hospital

    Prague, 15030

Other trials in Czechia

Spain1 site
  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026

Other trials in Spain

About this study

Aim of the study is to compare the safety and efficacy of pulmonary vein isolation using the endoscopic ablation system in comparison to irrigated radiofrequency current ablation in patients with drug-refractory persistent atrial fibrillation.

Being tested
HeartLight(TM) Laser Balloon, irrigated radiofrequency current ablation
Medical subject headings
Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HeartLight(TM) Laser BalloonDevice

    With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided

  • irrigated radiofrequency current ablationDevice

    The irrigated radiofrequency current ablation is used for pulmonary vein isolation

Study groups in NCT01863472
Study groupRoleWhat they receive
HeartLight(TM) Laser BalloonActive comparatorSafety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
Receives: Device: HeartLight(TM) Laser Balloon
irrigated radiofrequency current ablationActive comparatorSafety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
Receives: Device: irrigated radiofrequency current ablation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Documented recurrence of atrial fibrillation or any atrial tachyarrhythmia >30 seconds

    Measured: between day 90 and 365 days after index procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2013 (estimated)
  2. Study startJun 2013
  3. Primary completionSep 2016
  4. Study completionNov 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
152 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01863472
Sponsor's protocol ID
FF20/13 Version 03
Status last verified
Nov 2016
First submitted
19 May 2013
Last updated
21 Nov 2016
Results posted
No
Data monitoring committee
No

Publications

  • Schmidt B, Neuzil P, Luik A, Osca Asensi J, Schrickel JW, Deneke T, Bordignon S, Petru J, Merkel M, Sediva L, Klostermann A, Perrotta L, Cano O, Chun KRJ. Laser Balloon or Wide-Area Circumferential Irrigated Radiofrequency Ablation for Persistent Atrial Fibrillation: A Multicenter Prospective Randomized Study. Circ Arrhythm Electrophysiol. 2017 Dec;10(12):e005767. doi: 10.1161/CIRCEP.117.005767.

    PubMed 29217521

Questions about this trial

What is this clinical trial studying?

A study testing HeartLight(TM) Laser Balloon and irrigated radiofrequency current ablation in people with Persistent Atrial Fibrillation, run by Boris Schmidt at 6 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 6 sites in Germany, Czechia, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Documented recurrence of atrial fibrillation or any atrial tachyarrhythmia >30 seconds (time frame: between day 90 and 365 days after index procedure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01863472, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in